2021
Chapter 43 HIV and Other Retroviral Infections of the Nervous System
Peluso M, Spudich S. Chapter 43 HIV and Other Retroviral Infections of the Nervous System. 2021, 765-784. DOI: 10.1016/b978-0-12-819306-8.00043-5.Peer-Reviewed Original ResearchAntiretroviral therapyHIV infectionNeurologic manifestationsHuman immunodeficiency virus (HIV) infectionEra of ARTSuccessful systemic treatmentImmunodeficiency virus infectionEarly HIV infectionSystemic immune systemQuality of lifeAdvanced immunosuppressionAntiretroviral statusNeurologic complicationsNeurologic presentationSystemic treatmentVirus infectionCNS effectsCognitive disordersNervous systemImmune systemInfectionRetroviral infectionComplicationsHIVTherapy
2019
Treatment of Central Nervous System Manifestations of HIV in the Current Era
Handoko R, Spudich S. Treatment of Central Nervous System Manifestations of HIV in the Current Era. Seminars In Neurology 2019, 39: 391-398. PMID: 31378874, DOI: 10.1055/s-0039-1688915.Peer-Reviewed Original ResearchConceptsCSF HIVTreatment intensificationCentral nervous system opportunistic infectionsHuman immunodeficiency virus (HIV) infectionCentral nervous system manifestationsCurrent ARV regimenHIV resistance mutationsNeuropsychiatric adverse effectsImmunodeficiency virus infectionNervous system manifestationsNeuropsychiatric side effectsMagnetic resonance imagingCerebrospinal fluid dataSystemic HIVHigh CNS penetrationARV regimenSystem manifestationsOpportunistic infectionsHIV replicationTreatment switchLumbar punctureSleep disturbancesVirus infectionCCR5 inhibitorsNeuropsychiatric impairmentVery Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma
Hellmuth J, Slike BM, Sacdalan C, Best J, Kroon E, Phanuphak N, Fletcher JLK, Prueksakaew P, Jagodzinski LL, Valcour V, Robb M, Ananworanich J, Allen IE, Krebs SJ, Spudich S. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma. The Journal Of Infectious Diseases 2019, 220: 1885-1891. PMID: 30668739, PMCID: PMC6833977, DOI: 10.1093/infdis/jiz030.Peer-Reviewed Original ResearchConceptsAcute HIV infectionAntiretroviral therapyART initiationCerebrospinal fluidWeek 96Week 24HIV infectionImmune activationAHI groupHuman immunodeficiency virus (HIV) infectionEarly ART initiationPlasma CCL2 levelsTrajectory of HIVChronic immune activationImmune activation markersSuppressive antiretroviral therapyImmunodeficiency virus infectionInterleukin-6 levelsMarkers of inflammationPlasma neopterin levelsWeeks of treatmentCentral nervous systemART regimenCCL2 levelsNeopterin levels
2018
Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities
D’Antoni M, Byron MM, Chan P, Sailasuta N, Sacdalan C, Sithinamsuwan P, Tipsuk S, Pinyakorn S, Kroon E, Slike BM, Krebs SJ, Khadka VS, Chalermchai T, Kallianpur KJ, Robb M, Spudich S, Valcour V, Ananworanich J, Ndhlovu LC, Teeratakulpisarn N, Fletcher J, Sacdalan C, Chomchey N, Sutthichom D, Rattanamanee S, Prueksakaew P, Ubolyam S, Eamyoung P, Puttamaswin S, Karnsomlap P, Luekasemsuk T, Intasan J, Benjapornpong K, Ratnaratorn N, O’Connell R, Trichavaroj R, Akapirat S, Phuang-Ngern Y, Sukhumvittaya S, Sajjaweerawan C, Jongrakthaitae S, Saetun P, Tragonlugsana N, Nuntapinit B, Tantibul N, Savadsuk H, Michael N, Trautmann L, Tovanabutra S, Ouellette M, Butterworth O, Crowell T, Turk E, Eller L, Milazzo M, Bandar I, Shiramizu B, Shikuma C. Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. The Journal Of Infectious Diseases 2018, 218: 1453-1463. PMID: 29868826, PMCID: PMC6151077, DOI: 10.1093/infdis/jiy337.Peer-Reviewed Original ResearchConceptsAcute HIV infectionFiebig stage IIIStage I/IISoluble CD163 levelsHIV infectionCentral nervous systemStage IIICD163 levelsCerebrospinal fluidUninfected controlsChronic human immunodeficiency virus (HIV) infectionCombination antiretroviral therapy (cART) initiationHuman immunodeficiency virus (HIV) infectionInitiation of cARTAntiretroviral therapy initiationImmunodeficiency virus infectionEnzyme-linked immunosorbentCART initiationMyeloid activationAntiretroviral therapyChronic HIVCNS involvementSCD163 levelsTherapy initiationActivation markersCentral Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques
Hsu DC, Sunyakumthorn P, Wegner M, Schuetz A, Silsorn D, Estes JD, Deleage C, Tomusange K, Lakhashe SK, Ruprecht RM, Lombardini E, Im-Erbsin R, Kuncharin Y, Phuang-Ngern Y, Inthawong D, Chuenarom W, Burke R, Robb ML, Ndhlovu LC, Ananworanich J, Valcour V, O'Connell RJ, Spudich S, Michael NL, Vasan S. Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques. Journal Of Virology 2018, 92: 10.1128/jvi.00222-18. PMID: 29563297, PMCID: PMC5952152, DOI: 10.1128/jvi.00222-18.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CDAntigens, Differentiation, MyelomonocyticBrainCD4 Lymphocyte CountCD4-Positive T-LymphocytesCells, CulturedDisease Models, AnimalHIV-1HumansMacaca mulattaMacrophagesMeningesMicrogliaMonocytesParenchymal TissueReceptors, Cell SurfaceRNA, ViralSimian Acquired Immunodeficiency SyndromeSimian immunodeficiency virusViral LoadConceptsSimian-human immunodeficiency virusSimian immunodeficiency virusCD68/CD163Immunodeficiency virus infectionCentral nervous systemBrain parenchymaHIV envelopeImmunodeficiency virusVirus infectionEarly human immunodeficiency virus (HIV) infectionSimian-human immunodeficiency virus (SHIV) infectionCentral nervous system inflammationHuman immunodeficiency virus (HIV) infectionCentral nervous system involvementPathogenic simian immunodeficiency virusRhesus macaquesT-cell-mediated processEarly clinical courseSHIV-infected animalsNervous system inflammationT-cell countsCell-mediated inflammationNervous system involvementEnd-stage diseaseHIV cure strategiesLongitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection
Sanford R, Ances BM, Meyerhoff DJ, Price RW, Fuchs D, Zetterberg H, Spudich S, Collins DL. Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 2018, 67: 1697-1704. PMID: 29697762, PMCID: PMC6233681, DOI: 10.1093/cid/ciy362.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyHuman immunodeficiency virusPrimary HIV infectionChronic HIV infectionCortical thicknessHIV infectionCortical thinningUntreated infectionTemporal lobeBrain volumeImpact of HIVPrimary human immunodeficiency virus (HIV) infectionEarly combination antiretroviral therapyUntreated human immunodeficiency virusHuman immunodeficiency virus (HIV) infectionLongitudinal magnetic resonance imagingImmunodeficiency virus infectionCerebrospinal fluid biomarkersStructural brain changesCortical gray matterMagnetic resonance imagingBrain morphometric measuresCART durationAntiretroviral therapySubcortical atrophy
2017
Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy
Rahimy E, Li FY, Hagberg L, Fuchs D, Robertson K, Meyerhoff DJ, Zetterberg H, Price RW, Gisslén M, Spudich S. Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy. The Journal Of Infectious Diseases 2017, 215: 1132-1140. PMID: 28368497, PMCID: PMC5426376, DOI: 10.1093/infdis/jix013.Peer-Reviewed Original ResearchConceptsPrimary HIV infectionCombination antiretroviral therapyHIV infectionNeurofilament light chainAntiretroviral therapyCreatinine levelsCerebrospinal fluidN-acetylaspartateAbnormal blood-brain barrier (BBB) permeabilityPrimary human immunodeficiency virus (HIV) infectionBlood-brain barrier disruptionHuman immunodeficiency virus (HIV) infectionBlood-brain barrier permeabilityNeuropsychological performanceImmunodeficiency virus infectionParietal gray matterYears of treatmentLongitudinal observational studyCART durationCART initiationMedian intervalNeuronal injuryAlbumin quotientNfL levelsCSF levels
2016
Past Substance Use Affects Central Nervous System (CNS) Inflammation in Human Immunodeficiency Virus Infection
Chen L, Peterson J, Robertson K, Fuchs D, Price R, Spudich S. Past Substance Use Affects Central Nervous System (CNS) Inflammation in Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases 2016, 3: 853. DOI: 10.1093/ofid/ofw194.60.Peer-Reviewed Original Research
2015
Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection
Peluso MJ, Valcour V, Ananworanich J, Sithinamsuwan P, Chalermchai T, Fletcher JL, Lerdlum S, Chomchey N, Slike B, Sailasuta N, Gisslén M, Zetterberg H, Spudich S, Teams O. Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection. The Journal Of Infectious Diseases 2015, 212: 1759-1767. PMID: 25995196, PMCID: PMC4633761, DOI: 10.1093/infdis/jiv296.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyAcute HIV infectionCSF NfL levelsNeurofilament light chainChronic HIV infectionHIV infectionNfL levelsParietal gray matterFrontal white matterNeuronal injuryAcute infectionGray matterCART initiationAntiretroviral therapyAcute human immunodeficiency virus (HIV) infectionCerebrospinal fluid neurofilament light chainProton magnetic resonance spectroscopic findingsWhite matterHuman immunodeficiency virus (HIV) infectionN-acetylaspartate/creatineMagnetic resonance spectroscopic findingsImmediate antiretroviral therapyImmunodeficiency virus infectionFrontal gray matterAxonal injury
2014
Chapter 44 HIV and other Retroviral Infections of the Nervous System
Peluso M, Spudich S. Chapter 44 HIV and other Retroviral Infections of the Nervous System. 2014, 885-909. DOI: 10.1016/b978-0-12-407710-2.00044-8.Peer-Reviewed Original ResearchCombination antiretroviral therapyHIV infectionNeurologic manifestationsEra of cARTHuman immunodeficiency virus (HIV) infectionSuccessful systemic treatmentImmunodeficiency virus infectionEarly HIV infectionSystemic immune systemQuality of lifeAdvanced immunosuppressionAntiretroviral statusAntiretroviral therapyNeurologic complicationsNeurologic presentationSystemic treatmentVirus infectionCNS effectsCognitive disordersNervous systemImmune systemInfectionRetroviral infectionComplicationsHIV
2013
Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection
Peluso MJ, Meyerhoff DJ, Price RW, Peterson J, Lee E, Young AC, Walter R, Fuchs D, Brew BJ, Cinque P, Robertson K, Hagberg L, Zetterberg H, Gisslén M, Spudich S. Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection. The Journal Of Infectious Diseases 2013, 207: 1703-1712. PMID: 23460748, PMCID: PMC3636785, DOI: 10.1093/infdis/jit088.Peer-Reviewed Original ResearchConceptsPrimary HIV infectionNeurofilament light chainHIV infectionAmyloid precursor proteinCerebrospinal fluidNeuronal injuryT-tauCSF/plasma albumin ratioPrimary human immunodeficiency virus (HIV) infectionCentral nervous system inflammationHuman immunodeficiency virus (HIV) infectionSoluble amyloid precursor proteinGamma-induced protein 10Primary infection groupNervous system inflammationImmunodeficiency virus infectionEarly neuronal injuryPlasma albumin ratioParietal gray matterGlutamate/creatineLight chainPrecursor proteinProton magnetic resonance spectroscopyFrontal white matterWhite blood cells
2012
Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection
Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, Suwanwela NC, Jagodzinski L, Michael N, Spudich S, van Griensven F, de Souza M, Kim J, Ananworanich J. Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection. The Journal Of Infectious Diseases 2012, 206: 275-282. PMID: 22551810, PMCID: PMC3490695, DOI: 10.1093/infdis/jis326.Peer-Reviewed Original ResearchConceptsHIV RNA levelsAcute HIV infectionCSF HIV RNA levelsCopies/mLHIV infectionCerebrospinal fluidHIV RNARNA levelsPlasma HIV RNA levelsCentral nervous system eventsHuman immunodeficiency virus (HIV) infectionCSF HIV RNAFiebig stages IIntrathecal immune activationAcute retroviral syndromeImmunodeficiency virus infectionNervous system eventsMagnetic resonance imagingMagnetic resonance spectroscopy characterizationCSF neopterinBrain inflammationCNS inflammationCSF levelsHIV transmissionImmune activation
2011
Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden
Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW. Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. The Journal Of Infectious Diseases 2011, 204: 753-760. PMID: 21844301, PMCID: PMC3156103, DOI: 10.1093/infdis/jir387.Peer-Reviewed Original ResearchConceptsWhite blood cell countCSF HIV RNAPrimary HIV infectionHIV RNACerebrospinal fluidPHI participantsImmune activationAlbumin ratioPrimary human immunodeficiency virus-1 infectionCentral nervous system immune activationCSF white blood cell countHuman immunodeficiency virus-1 (HIV-1) infectionHuman immunodeficiency virus (HIV) infectionHigher albumin ratioHIV-seronegative controlsImmunodeficiency virus infectionHIV-seronegative participantsCells/μLLow cerebrospinal fluidBlood cell countVirus-1 infectionCross-sectional studyMagnitude of infectionCXCL10 concentrationsPHI patients